Zobrazeno 1 - 10
of 409
pro vyhledávání: '"Bernard A. Fox"'
Autor:
Paolo A. Ascierto, Sanjiv S. Agarwala, Allison Betof Warner, Marc S. Ernstoff, Bernard A. Fox, Thomas F. Gajewski, Jérôme Galon, Claus Garbe, Brian R. Gastman, Jeffrey E. Gershenwald, Pawel Kalinski, Michelle Krogsgaard, Rom S. Leidner, Roger S. Lo, Alexander M. Menzies, Olivier Michielin, Poulikos I. Poulikakos, Jeffrey S. Weber, Corrado Caracò, Iman Osman, Igor Puzanov, Magdalena Thurin
Publikováno v:
Journal of Translational Medicine, Vol 21, Iss 1, Pp 1-17 (2023)
Abstract Outcomes for patients with melanoma have improved over the past decade with the clinical development and approval of immunotherapies targeting immune checkpoint receptors such as programmed death-1 (PD-1), programmed death ligand 1 (PD-L1) o
Externí odkaz:
https://doaj.org/article/06bb97ac823040b3bb11134f118a0c11
Autor:
Paolo A. Ascierto, Antonio Avallone, Carlo Bifulco, Sergio Bracarda, Joshua D. Brody, Leisha A. Emens, Robert L. Ferris, Silvia C. Formenti, Omid Hamid, Douglas B. Johnson, Tomas Kirchhoff, Christopher A. Klebanoff, Gregory B. Lesinski, Anne Monette, Bart Neyns, Kunle Odunsi, Chrystal M. Paulos, Daniel J. Powell, Katayoun Rezvani, Brahm H. Segal, Nathan Singh, Ryan J. Sullivan, Bernard A. Fox, Igor Puzanov
Publikováno v:
Journal of Translational Medicine, Vol 21, Iss 1, Pp 1-21 (2023)
Abstract The discovery and development of novel treatments that harness the patient’s immune system and prevent immune escape has dramatically improved outcomes for patients across cancer types. However, not all patients respond to immunotherapy, a
Externí odkaz:
https://doaj.org/article/627c0bedba0a40d4b9dd41c55b9dde62
Autor:
Paolo A. Ascierto, Renier Brentjens, Samir N. Khleif, Kunle Odunsi, Katayoun Rezvani, Marco Ruella, Ryan J. Sullivan, Bernard A. Fox, Igor Puzanov
Publikováno v:
Journal of Translational Medicine, Vol 21, Iss 1, Pp 1-10 (2023)
Abstract The 2022 Immunotherapy Bridge congress (November 30–December 1, Naples, Italy) featured a Great Debate session which addressed three contemporary topics in the field of immunotherapy. The debates included counterpoint views from leading ex
Externí odkaz:
https://doaj.org/article/86cf15cf8d4442faa9a75236149ec41e
Autor:
Paolo A. Ascierto, Sanjiv S. Agarwala, Christian Blank, Corrado Caracò, Richard D. Carvajal, Marc S. Ernstoff, Soldano Ferrone, Bernard A. Fox, Thomas F. Gajewski, Claus Garbe, Jean-Jacques Grob, Omid Hamid, Michelle Krogsgaard, Roger S. Lo, Amanda W. Lund, Gabriele Madonna, Olivier Michielin, Bart Neyns, Iman Osman, Solange Peters, Poulikos I. Poulikakos, Sergio A. Quezada, Bradley Reinfeld, Laurence Zitvogel, Igor Puzanov, Magdalena Thurin
Publikováno v:
Journal of Translational Medicine, Vol 20, Iss 1, Pp 1-21 (2022)
Abstract Advances in immune checkpoint and combination therapy have led to improvement in overall survival for patients with advanced melanoma. Improved understanding of the tumor, tumor microenvironment and tumor immune-evasion mechanisms has result
Externí odkaz:
https://doaj.org/article/eceaa54ada8b4252a49fcbe967456d2a
Autor:
Robert Saddawi-Konefka, Aoife O’Farrell, Farhoud Faraji, Lauren Clubb, Michael M. Allevato, Shawn M. Jensen, Bryan S. Yung, Zhiyong Wang, Victoria H. Wu, Nana-Ama Anang, Riyam Al Msari, Shiruyeh Schokrpur, Ida Franiak Pietryga, Alfredo A. Molinolo, Jill P. Mesirov, Aaron B. Simon, Bernard A. Fox, Jack D. Bui, Andrew Sharabi, Ezra E. W. Cohen, Joseph A. Califano, J. Silvio Gutkind
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-19 (2022)
Response rates to immune checkpoint inhibitors (ICI) in patients with head and neck squamous cell carcinoma (HNSCC) remain low. Here the authors show that ablative treatment of tumor-draining regional lymphatics, a standard of care approach in patien
Externí odkaz:
https://doaj.org/article/45b1c1184762403b85513f3b2ecdf50e
Autor:
Paolo A. Ascierto, Antonio Avallone, Nina Bhardwaj, Carlo Bifulco, Sergio Bracarda, Joshua D. Brody, Luigi Buonaguro, Sandra Demaria, Leisha A. Emens, Robert L. Ferris, Jérôme Galon, Samir N. Khleif, Christopher A. Klebanoff, Tamara Laskowski, Ignacio Melero, Chrystal M. Paulos, Sandro Pignata, Marco Ruella, Inge Marie Svane, Janis M. Taube, Bernard A. Fox, Patrick Hwu, Igor Puzanov
Publikováno v:
Journal of Translational Medicine, Vol 20, Iss 1, Pp 1-19 (2022)
Abstract Over the past decade, immunotherapy has become an increasingly fundamental modality in the treatment of cancer. The positive impact of immune checkpoint inhibition, especially anti-programmed death (PD)-1/PD-ligand (L)1 blockade, in patients
Externí odkaz:
https://doaj.org/article/c7c0a3307fce4f8da5d3d700a08bd2c5
Autor:
Jesse R. Qualliotine, Takuya Nakagawa, Sara Brin Rosenthal, Sayed Sadat, Carmen Ballesteros-Merino, Guorong Xu, Adam Mark, Art Nasamran, J. Silvio Gutkind, Kathleen M. Fisch, Theresa Guo, Bernard A. Fox, Zubair Khan, Alfredo A. Molinolo, Joseph A. Califano
Publikováno v:
Cancers, Vol 15, Iss 17, p 4379 (2023)
HPV-associated oropharynx carcinoma (HPVOPC) tumors have a relatively low mutational burden. Elucidating the relative contributions of other tumor alterations, such as DNA methylation alterations, alternative splicing events (ASE), and copy number va
Externí odkaz:
https://doaj.org/article/d1dbdaab5b124713ae06bddf1001f66c
Autor:
Paolo A. Ascierto, Lisa H. Butterfield, Olivera J. Finn, Andrew Futreal, Omid Hamid, Theresa LaVallee, Michael A. Postow, Igor Puzanov, Jeffrey Sosman, Bernard A. Fox, Patrick Hwu
Publikováno v:
Journal of Translational Medicine, Vol 20, Iss 1, Pp 1-13 (2022)
Abstract As part of the 2021 Immunotherapy Bridge virtual congress (December 1–2, Naples, Italy), the Great Debate sessions featured experts who were assigned counter opposing views on four important questions in immunotherapy today. The first topi
Externí odkaz:
https://doaj.org/article/b62868dd06ff48669cf032113f06cffc
Autor:
Rebekka Duhen, Michael Beymer, Shawn M. Jensen, Srinivas Abbina, Suraj Abraham, Nikita Jain, Anitha Thomas, Andrew J. Geall, Hong-Ming Hu, Bernard A. Fox, Andrew D. Weinberg
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
To prevent SARS-CoV-2 infections and generate long-lasting immunity, vaccines need to generate strong viral-specific B and T cell responses. Previous results from our lab and others have shown that immunizations in the presence of an OX40 agonist ant
Externí odkaz:
https://doaj.org/article/b5aca7d566d943a9a319e45e455b3eb4
Autor:
Paolo A. Ascierto, Carlo Bifulco, Fortunato Ciardiello, Sandra Demaria, Leisha A. Emens, Robert Ferris, Silvia C. Formenti, Jerome Galon, Samir N. Khleif, Tomas Kirchhoff, Jennifer McQuade, Kunle Odunsi, Akash Patnaik, Chrystal M. Paulos, Janis M. Taube, John Timmerman, Bernard A. Fox, Patrick Hwu, Igor Puzanov
Publikováno v:
Journal of Translational Medicine, Vol 19, Iss 1, Pp 1-16 (2021)
Abstract Improved understanding of tumor immunology has enabled the development of therapies that harness the immune system and prevent immune escape. Numerous clinical trials and real-world experience has provided evidence of the potential for long-
Externí odkaz:
https://doaj.org/article/07442960a2f94c70a8eca356003aaba9